首页> 外国专利> METHOD FOR PRODUCING CELL-NATURAL KILLERS AND DENDRIT CELLS FROM HUMAN EMBRYONAL HEMANGIO REGIONS OBTAINED FROM STEM CELLS

METHOD FOR PRODUCING CELL-NATURAL KILLERS AND DENDRIT CELLS FROM HUMAN EMBRYONAL HEMANGIO REGIONS OBTAINED FROM STEM CELLS

机译:从干细胞获得的人胚半球区域生产细胞杀伤性细胞和树突状细胞的方法

摘要

1. A method for producing natural killer (NK) cells, including: producing hemangioblasts; culturing hemangioblasts on methyl cellulose and a first cytokine mixture containing IL2, IL3, IL6, IL7, IL15, SCF and FL; collecting cultured cells; cultivating the collected cells in a liquid medium containing human serum and a second mixture of cytokines consisting of IL7, IL15, SCF and FL to obtain NK cells. 2. The method according to claim 1, characterized in that methyl cellulose is methyl cellulose H4236.3. The method according to claim 1, characterized in that methyl cellulose is methyl cellulose H4536.4. The method according to claim 1, characterized in that the concentration of IL2 is about 5-10 ng / ml, IL3 is about 1-10 ng / ml, IL6 is about 1-10 ng / ml, IL7 is about 5-20 ng / ml IL15 is about 5-10 ng / ml, SCF is about 10-50 ng / ml, and FL is about 10-50 ng / ml. 5. The method according to claim 1, characterized in that the cultivation of hemangioblasts is carried out approximately 6-8 days. The method according to claim 1, characterized in that the cultivation of the collected cells is carried out approximately 14-21 days. The method according to claim 1, characterized in that it further includes a weekly replacement medium for updating the second mixture of cytokines. The method according to claim 1, characterized in that the hemangioblasts differentiate from human embryonic stem cells (hESC). The method according to claim 1, characterized in that hemangioblasts differentiate from induced pluripotent (iPS) cells. The method according to claim 1, characterized in that the NK cells are immature NK cells and are CD56 + and CD16-.11. The method according to claim 1, characterized in that the NK cells are mature NK cells and are CD56- and CD16 +, or CD56lo and CD16 + .12. Natural killer cells (NK) obtained by any of the methods according to claims 1-11.13. Pharmaceutically acceptable composition
机译:1.产生自然杀伤(NK)细胞的方法,包括:产生成血管细胞;在甲基纤维素和包含IL2,IL3,IL6,IL7,IL15,SCF和FL的第一细胞因子混合物中培养成血管细胞;收集培养的细胞;在含有人血清和由IL7,IL15,SCF和FL组成的第二种细胞因子混合物的液体培养基中培养收集的细胞,以获得NK细胞。 2.根据权利要求1所述的方法,其特征在于,甲基纤维素是甲基纤维素H4236.3。 2.根据权利要求1所述的方法,其特征在于,甲基纤维素为甲基纤维素H4536.4。 2.根据权利要求1所述的方法,其特征在于,IL2的浓度为约5-10ng / ml,IL3为约1-10ng / ml,IL6为约1-10ng / ml,IL7为约5-20ng。 / ml IL15约为5-10 ng / ml,SCF约为10-50 ng / ml,FL约为10-50 ng / ml。 5.根据权利要求1的方法,其特征在于成血成血管细胞的培养进行约6-8天。 2.根据权利要求1所述的方法,其特征在于,收集的细胞的培养进行约14-21天。 2.根据权利要求1所述的方法,其特征在于,所述方法还包括每周更换培养基以更新所述第二种细胞因子混合物。 2.根据权利要求1所述的方法,其特征在于,所述成血管细胞与人胚胎干细胞(hESC)分化。 2.根据权利要求1所述的方法,其特征在于,成血成血管细胞与诱导多能性(iPS)细胞分化。 2.根据权利要求1所述的方法,其特征在于,所述NK细胞是未成熟的NK细胞,并且是CD56 +和CD16-.11。 2.根据权利要求1所述的方法,其特征在于,所述NK细胞是成熟的NK细胞,并且是CD56-和CD16 +或CD56lo和CD16 + .12。权利要求1-11.13中任一项方法获得的天然杀伤细胞(NK)。药学上可接受的组合物

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号